IHC with the anti-BRAF V600E (VE1) antibody on the same tissue also confirmed expression
of the BRAF V600E protein in HS tumour cells (Figure. A and B). A, HE staining of inguinal …

Histiocytic sarcoma (HS) is an extremely rare but aggressive hematopoietic malignancy, and
the prognosis has been reported to be rather unfavorable with a median overall survival of …

Histiocytic sarcoma is a rare malignant neoplasm arising most commonly in lymph nodes,
intestinal tract, skin and soft tissue. The incidence of primary CNS histiocytic sarcoma is …

4. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome
in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after …

Histiocytic sarcoma (HS) is an extremely rare non-Langerhans histiocytic neoplasm that can
present as unifocal or multifocal extranodal disease. 1 The limited reports available for this …

Abstract Introduction: BRAF V600E substitution predicts sensitivity of a cancer to BRAF
inhibitor therapy. The mutation is rarely found in soft-tissue sarcomas. Here we describe a …

ABSTRACT MAPK has been reported as a key oncogenic pathway for canine histiocytic
sarcoma, which can be pharmacologically targeted with trametinib, a small inhibitor of …

The precise cause of HS/DCS is still unknown. The relatively low incidence in humans urges
for an animal model with a high incidence to accelerate knowledge about genetics and …

Malignant histiocytosis (MH) is an extremely rare neoplasm of the macrophage–dendritic
cell lineage. We report the clinical characteristics, molecular aberrations, treatments, and …

EZH2 is an important enzymatic subunit of the epigenetic regulator polycomb repressive
complex 2 (PRC2), which controls gene silencing through post-translational modification …